Down-regulation of hepatic lipase expression in experimental nephrotic syndrome

Kidney International

Volumn 51, Issue 6, 1997, Pages 1933-1937

  Liang, Kaihui ^a   Vaziri, Nosratola D ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TRIACYLGLYCEROL LIPASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; GENE EXPRESSION; LIVER; MALE; NEPHROTIC SYNDROME; NONHUMAN; PRIORITY JOURNAL; RAT;

EID: 0030953206     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1038/ki.1997.263     Document Type: Article

References (31)

1. DICHEK HL, PARROTT C, RONAN R, BRUNZELL JD, BREWER HB JR, SANTA MARINA-FOJO S: Functional characterization of chimeric lipase genetically engineered from human lipoprotein lipase and human hepatic lipase. J Lipid Res 34:1393-1401, 1993
2. SEMENKOVICH CF, CHEN SH, WIMS M, LUO CC, LI WH, CHAN L: Lipoprotein lipase and hepatic lipase mRNA tissue specific expression, developmental regulation, and evolution. J Lipid Res 30:423-431, 1989
3. JANSEN H, VAN BERKEL TJ, HULSMANN WC: Binding of liver lipase to parenchymal and non-parenchymal rat liver cells. Biochem Biophys Res Commun 85:148-152, 1978
4. DEMANT T, CARLSON LA, HOLMQUIST L, KARPE F, NILSSON-EHLE P, PACKARD CJ, SHEPHERD J: Lipoprotein metabolism in hepatic lipase deficiency: Studies on the turnover of apolipoprotein B and on the effect of hepatic lipase on high density lipoprotein. J Lipid Res 29:1603-1611, 1988
5. SULTAN F, LAGRANGE D, JANSEN H, GRIGLIO S: Inhibition of hepatic lipase activity impairs chylomicron remnant removal. Biochim Biophys Acta 1042:150-152, 1990
6. MOWRI HO, PATSCH W, SMITH LC, GOTTO AM JR, PATSCH JR: Different reactivities of high density lipoprotein 2 subfractions with hepatic lipase. J Lipid Res 33:1269-1279, 1992
7. LIANG K, VAZIRI ND: Gene expression of lipoprotein lipase in experimental nephrosis. J Lab Clin Med (in press)
8. BEISIEGEL U, WEBER W, BENGTSSON-OLIVECRONA G: Lipoprotein lipase enhances the binding of chylomicrons to low-density lipoprotein receptor-related protein. Proc Nat Acad Sci USA 88:8342-8346, 1991
9. KAYSEN GA: Hyperlipidemia of the nephrotic syndrome. Kidney Int 39(Suppl 31):S8-S15, 1991
10. MARSH JB: Lipoprotein metabolism in experimental nephrosis. J Lipid Res 25:1619-1623, 1984
11. STAPRANS I, FELTS JM, COUSER WG: Glycosaminoglycans and chylomicron metabolism in control and nephrotic rats. Metabolism 36:496-501, 1987
12. JOVEN J, VILLABONA C, VILELLA E, MASANA L, ALBERTI R, VALLES M: Abnormalities of lipoprotein metabolism in patients with the nephrotic syndrome. N Engl J Med 323:579-584, 1990
13. GHERARDI E, ROTA E, CALANDRA S, GENOVA R, TAMBORINO A: Relationship among the concentrations of serum lipoproteins and changes in their chemical composition in patients with untreated nephrotic syndrome. Eur J Clin Invest 7:563-570, 1977
14. STENVINKEL P, BERGLUND L, HEIMBURGER O, PETTERSON E, ALVESTRAND A: Lipoprotein(a) in nephrotic syndrome. Kidney Int 44:1116-1123, 1993
15. LEVY E, ZIV E, BAR-ON H, SHAFRIR E: Experimental nephrotic syndrome: Removal and tissue distribution of chylomicrons and very-low density lipoproteins of normal and nephrotic origin. Biochim Biophys Acta 1043:259-266, 1990
16. KRONENBERG F, UTERMAN G, DIEPLINGER H: Lipoprotein (a) in renal diseases. Am J Kidney Dis 27:1-25, 1996
17. KAYSEN GA, MEHENDRU L, PAN XM, STAPRANS I: Both peripheral chylomicron catabolism and hepatic uptake of remnants are defective in nephrosis. Am J Physiol 263:F335-F341, 1992
18. KOMAROMY MC, SCHOTZ MC: Cloning of rat hepatic lipase cDNA: Evidence for a lipase gene family. Proc Natl Acad Sci USA 84:1526-1530, 1987
19. VAZIRI ND, LIANG KH: Down regulation of hepatic LDL receptor in experimental nephrosis. Kidney Int 50:887-893, 1996
20. CHRISTIAN E, KUUSI T: Preparation, characterization and measurement of hepatic lipase. Meth Enzymol 129:716-738, 1986
21. DOOLITTLE MH, WONG H, DAVIS RC, SCHOTZ MC: Synthesis of hepatic lipase in liver and extrahepatic tissues. J Lipid Res 28:1326-1334, 1987
22. JOVEN J, VILLABONA C, VILELLA E, MASANA L, ALBERTI R, VALLES M: Abnormalities of lipoprotein metabolism in patients with nephrotic syndrome. N Engl J Med 323:579-584, 1990
23. GHERARDI E, ROTA E, CALANDRA S, GENOVA R, TAMBORINO A: Relationship among the concentrations of serum lipoproteins and changes in their chemical composition in patients with untreated nephrotic syndrome. Eur J Clin Invest 7:563-570, 1977
24. KLIN M, SMOGORZEWSKI M, NI Z, ZHANG G, MASSRY SG: Abnormalities in hepatic lipase in chronic renal failure: Role of excess parathyroid hormone. J Clin Invest 97:2167-2173, 1996
25. VAZIRI ND, LIANG K: Down regulation of tissue lipoprotein lipase expression in experimental chronic renal failure. Kidney Int 50:1928-1935, 1996
26. VAZIRI ND, LIANG KH: Down regulation of VLDL receptor expression in chronic experimental renal failure. Kidney Int 51:913-919, 1997
27. LIANG KH, VAZIRI ND: Acquired VLDL receptor deficiency in experimental nephrosis. Kidney Int 51:1761-1765, 1997
28. BENHIZIA F, LARANGE D, MALEWIAK MI, GRIGLIO S: In vitro regulation of hepatic lipase activity and mRNA levels by diets which modify cholesterol influx to the liver. Biochim Biophys Acta 1211:181-188, 1994
29. VAZIRI ND, LIANG KH: Hepatic HMG-CoA reductase gene expression in the course of puromycin-induced nephrosis. Kidney Int 48: 1979-1985, 1995
30. LIANG KH, OVEISI F, VAZIRI ND: Gene expression of hepatic cholesterol 7α-hydroxylase in the course of puromycin-induced nephrosis. Kidney Int 49:855-860, 1996
31. SHAFRIR E: Hyperlipoproteinemia of aminonucleoside-induced nephrotic syndrome: Modulation by glucocorticoids and triiodothyronine. Isr J Med Sci 32:390-397, 1996